Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > New Press Release - Sirona Biochem Initiates Private Placement

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Jan 26, 2024 11:48pm

111 Views

Post# 35848279

RE:New Press Release - Sirona Biochem Initiates Private Placement

Co should have never done the convertible debenture financing. The conversion into units is at $0.10 with the warrants exercisable at $0.15. As long as debenture holders can earn interest income they will not convert, especially when the interest income is paid out with shares at 25% discount of prevailing market price.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management